Matrix tablet permitting the sustained release of indapamide after oral administration
First Claim
Patent Images
1. A sustained release indapamide matrix tablet consisting essentially of between 1 and 2.5 mg of indapamide, polyvidone, methylhydroxyalkylcellulose, and excipient, which exhibits linear sustained release for at least eight hours, wherein 50 percent of the total quantity of indapamide is released over a period of between 5 and 14 hours, which produces blood levels in humans of between 20 and 80 ng/ml for up to 24 hours after oral administration, produced by a process consisting essentially of the steps of:
- (a) mixing indapamide with solid polyvidone having a molecular weight between 10,000 and 700,000 and an excipient;
(b) wetting the mixture of step (a) with an aqueous alcoholic solution to form a granulate;
(c) mixing the granulate with methylhydroxyalkylcellulose having a viscosity between 1,000 and 20,000 centipoises;
(d) lubricating the mixture of step (c) with a lubricating agent; and
(e) compressing the lubricated mixture of step (d) in a rotary tableting machine to produce a tablet having a hardness, measured by diametrical crushing, of 60 to 75N,wherein the percentages of indapamide, methylhydroxyalkylcellulose, and polyvidone are respectively approximately 1%, between 30 and 50 percent, and between 2 and 10 percent of the total mass of the tablet, the excipient consisting essentially of a compound selected from the group consisting of sugar, colloidal silica, and lubricant.
2 Assignments
0 Petitions
Accused Products
Abstract
The invention relates to a matrix tablet for the sustained release of indapamide which ensures a continuous and uniform release of the active principle after oral administration.
25 Citations
9 Claims
-
1. A sustained release indapamide matrix tablet consisting essentially of between 1 and 2.5 mg of indapamide, polyvidone, methylhydroxyalkylcellulose, and excipient, which exhibits linear sustained release for at least eight hours, wherein 50 percent of the total quantity of indapamide is released over a period of between 5 and 14 hours, which produces blood levels in humans of between 20 and 80 ng/ml for up to 24 hours after oral administration, produced by a process consisting essentially of the steps of:
-
(a) mixing indapamide with solid polyvidone having a molecular weight between 10,000 and 700,000 and an excipient; (b) wetting the mixture of step (a) with an aqueous alcoholic solution to form a granulate; (c) mixing the granulate with methylhydroxyalkylcellulose having a viscosity between 1,000 and 20,000 centipoises; (d) lubricating the mixture of step (c) with a lubricating agent; and (e) compressing the lubricated mixture of step (d) in a rotary tableting machine to produce a tablet having a hardness, measured by diametrical crushing, of 60 to 75N, wherein the percentages of indapamide, methylhydroxyalkylcellulose, and polyvidone are respectively approximately 1%, between 30 and 50 percent, and between 2 and 10 percent of the total mass of the tablet, the excipient consisting essentially of a compound selected from the group consisting of sugar, colloidal silica, and lubricant. - View Dependent Claims (2, 3, 4, 5, 6)
-
-
7. A process for producing a sustained release matrix tablet of indapamide consisting essentially of between 1 and 2.5 mg of indapamide, polyvidone, methylhydroxyalkylcellulose, and excipient, and exhibiting linear sustained release for at least eight hours, wherein 50 percent of the total quantity of indapamide is released over a period of between 5 and 14 hours to produce blood levels in humans of between 20 and 80 ng/ml for up to 24 hours after oral administration, consisting essentially of the steps of:
-
(a) mixing indapamide with solid polyvidone having a molecular weight between 10,000 and 700,000 and an excipient; (b) wetting the mixture of step (a) with an aqueous alcoholic solution to form a granulate; (c) mixing the granulate with methylhydroxyalkylcellulose having a viscosity between 1,000 and 20,000 centipoises; (d) lubricating the mixture of step (c) with a lubricating agent; and (e) compressing the lubricated mixture of step (d) in a rotary tableting machine to produce a tablet having a hardness, measured by diametrical crushing, of 60 to 75N; wherein the percentages of indapamide, methylhydroxylalkylcellulose, and polyvidone are respectively approximately 1%, between 30 and 50 percent, and between 2 and 20 percent of the total mass of the tablet, the excipient consisting essentially of a compound selected from the group consisting of sugar, colloidal silica, and lubricant. - View Dependent Claims (8, 9)
-
Specification